Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 205 of the 222 references it cites were found in a registry or an index; 39 of the 219 sources its claims cite were checked for support.
Abstract
OBJECTIVE: This clinical practice guideline addresses the diagnosis and treatment of primary adrenal insufficiency. PARTICIPANTS: The Task Force included a chair, selected by The Clinical Guidelines Subcommittee of the Endocrine Society, eight additional clinicians experienced with the disease, a methodologist, and a medical writer. The co-sponsoring associations (European Society of Endocrinology and the American Association for Clinical Chemistry) had participating members. The Task Force received no corporate funding or remuneration in connection with this review. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to determine the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: The evidence used to formulate recommendations was derived from two commissioned systematic reviews as well as other published systematic reviews and studies identified by the Task Force. The guideline was reviewed and approved sequentially by the Endocrine Society's Clinical Guidelines Subcommittee and Clinical Affairs Core Committee, members responding to a web posting, and the Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments. CONCLUSIONS: We recommend diagnostic tests for the exclusion of primary adrenal insufficiency in all patients with indicative clinical symptoms or signs. In particular, we suggest a low diagnostic (and therapeutic) threshold in acutely ill patients, as well as in patients with predisposing factors. This is also recommended for pregnant women with unexplained persistent nausea, fatigue, and hypotension. We recommend a short corticotropin test (250 μg) as the "gold standard" diagnostic tool to establish the diagnosis. If a short corticotropin test is not possible in the first instance, we recommend an initial screening procedure comprising the measurement of morning plasma ACTH and cortisol levels. Diagnosis of the underlying cause should include a validated assay of autoantibodies against 21-hydroxylase. In autoantibody-negative individuals, other causes should be sought. We recommend once-daily fludrocortisone (median, 0.1 mg) and hydrocortisone (15-25 mg/d) or cortisone acetate replacement (20-35 mg/d) applied in two to three daily doses in adults. In children, hydrocortisone (∼8 mg/m(2)/d) is recommended. Patients should be educated about stress dosing and equipped with a steroid card and glucocorticoid preparation for parenteral emergency administration. Follow-up should aim at monitoring appropriate dosing of corticosteroids and associated autoimmune diseases, particularly autoimmune thyroid disease.
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline provides evidence-based recommendations for diagnosing and treating primary adrenal insufficiency (PAI), emphasizing a low diagnostic threshold, the 250-µg short corticotropin test as the diagnostic gold standard, and glucocorticoid/mineralocorticoid replacement with adrenal crisis prevention. It also highlights major evidence gaps, including sparse randomized trial data for replacement regimens and limited diagnostic accuracy studies specifically in PAI.
Key findings
- For diagnosis, the guideline recommends testing patients with indicative symptoms/signs and using the standard-dose 250-µg corticotropin stimulation test as the “gold standard”; peak cortisol below 500 nmol/L (18 µg/dL) at 30 or 60 minutes indicates adrenal insufficiency. The high-dose ACTH stimulation test had a sensitivity of 92% (95% CI, 81–97%) for PAI based on five studies; no studies were available for the low-dose test in PAI. If corticotropin testing is not feasible, a morning cortisol <140 nmol/L (5 µg/dL) plus ACTH is suggested as a preliminary test.
- Autoimmune adrenalitis is the most common cause of PAI, accounting for up to 90% in Western countries; 21-hydroxylase autoantibodies should be measured, and about 30% of CYP21A2 autoantibody-positive individuals progressed to overt PAI during 5-year follow-up. In autoantibody-negative individuals, other causes should be sought, including adrenoleukodystrophy in males via very-long-chain fatty acids and adrenal CT for infiltrative or malignant disease.
- In adults, recommended replacement is hydrocortisone 15–25 mg/d or cortisone acetate 20–35 mg/d in two or three divided doses, with fludrocortisone starting at 50–100 µg/d (median, 0.1 mg) for confirmed aldosterone deficiency. Prednisolone 3–5 mg/d is an alternative, while dexamethasone is suggested against. DHEA replacement may be tried for 6 months in women with low libido, depressive symptoms, and/or low energy despite optimized replacement.
- For adrenal crisis, immediate parenteral hydrocortisone 100 mg (50 mg/m² for children) is recommended, followed by 200 mg/24 h (50–100 mg/m²/d for children), plus fluid resuscitation. Reported adrenal crisis frequencies were 6.6 crises/100 patient-years in a retrospective analysis of 444 patients and 8.3 crises/100 patient-years in a prospective study of 768 patient-years, with a crisis mortality rate of 0.5/100 patient-years.
Methods
- This is a GRADE-based clinical practice guideline developed by an Endocrine Society Task Force with a methodologist and medical writer; recommendations are graded strong (“we recommend,” 1) or weak (“we suggest,” 2), with evidence quality from QEEE (very low) to QQQQ (high), plus ungraded best practice statements.
- Evidence came from two commissioned systematic reviews and other published systematic reviews/studies. The first review compared high-dose vs low-dose ACTH stimulation for diagnosis and found only five studies for high-dose ACTH in PAI and none for low-dose ACTH in PAI. The second review compared glucocorticoid replacement regimens and identified 15 observational studies; mortality, bone density, and adrenal crisis data were very sparse or unavailable, and there was no statistically significant HRQoL difference between hydrocortisone dosages ≥30 mg/d vs <30 mg/d.
- The guideline was reviewed and approved sequentially by Endocrine Society committees, members responding to a web posting, and the Endocrine Society Council; the Task Force received no corporate funding or remuneration.
Limitations
- The paper states that the evidence base is limited: there are no randomized controlled trials for many treatment questions, diagnostic accuracy data for high-dose ACTH in PAI come from only five studies with none for low-dose ACTH in PAI, and the second systematic review found sparse or unavailable data on mortality, bone density, and adrenal crisis, with very low-quality evidence for extended-release/dual-release glucocorticoids. Many recommendations are weak or ungraded best practice statements.
- The paper states that cortisol cutoff values after corticotropin stimulation vary by assay, ACTH assays have analytical bias, and actual clinical cutpoints should be based on assay-specific normative data.
- Evident from the text: the guideline focuses only on PAI and explicitly excludes secondary adrenal insufficiency and critical illness-related corticosteroid insufficiency; some recommendations rely on clinical experience, unsystematic observations, and values/preferences rather than direct systematic evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Algorithm for the diagnostic approach to the patient with PAI. The most common causes of PAI are autoimmune destruction of the adrenal cortex in adults and CAH in children. These etiologies can be screened for using 21-hydroxylase antibodies and a baseline serum 17hydroxyprogesterone level. Males with negative 21-hydroxylase antibodies should be tested for adrenoleukodystrophy with plasma VLCFAs. If these diagnoses are excluded, a CT scan of the adrenals may reveal evidence of adrenal infiltrative processes or metastases. The individual's clinical picture and family history may render some steps in the algorithm redundant or suggest specific genetic syndromes. The latter includes subtypes of autoimmune polyglandular syndromes or specific rare genetic disorders where adrenal failure is part of a broader phenotype. A list of differential diagnoses is provided in Table 2. AHC, adrenal hypoplasia congenita; AI, adrenal insufficiency; VLCFA, very long chain fatty acid. a 17-OHprogesterone > 1000 ng/dL is diagnostic for 21-OH deficiency (14). b VLCFA should be measured in the initial evaluation of preadolescent boys. [Adapted from E. S. Husebye, et al: Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med . 2014;275:104-115 (181), with permission. © John Wiley & Sons, Inc.]](https://figures.cochat.ai/paper-figures/3d28d00e3ab049b5b513e655fd2f1f7a/diagnosis-and-treatment-of-primary-adrenal-insufficiency-an-endocrine-society-figure-1.png)
Verification
Claims the paper makes
35 Valid · 2 Not valid · 109 Not checked · 48 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, in all these reports, adrenal crisis was a significant cause of death.”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Disputedcites [149] 149. Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson G. Premature mortality in patients with Addison's disease: a pop- ulation-based study. J Clin Endocrinol Metab. 2006;91:4849 - 4853. sourceExperimental — accuracy not yet measured
The Mortality section reports 36 deaths attributed to adrenal insufficiency but explicitly says that no patient was reported to have died from adrenal crisis under ICD-10. It also cautions that ICD-9 cannot distinguish adrenal crisis from primary adrenal insufficiency, so the study does not establish crisis as a significant cause of death. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [150] 150. Bensing S, Brandt L, Tabaroj F, et al. Increased death risk and altered cancer incidence pattern in patients with isolated or com- bined autoimmune primary adrenocortical insufficiency. Clin En- docrinol (Oxf). 2008;69:697-704. source
- Not checked — no full text of the sourcecites [7] 7. Erichsen MM, Løvås K, Fougner KJ, et al. Normal overall mortality rate in Addison's disease, but young patients are at risk of prema- ture death. Eur J Endocrinol. 2009;160:233-237. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition to a paired sample of cortisol and ACTH, the adrenal reserve is appropriately and safely assessed in pregnancy by corticotropin stimulation, if indicated (40,41).”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Supportedcites [40] 40. Lebbe M, Arlt W. What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy? Clin Endocrinol (Oxf). 2013;78:497-502. source
The Investigations section (p. 3) calls the short Synacthen test a valid measure of adrenal cortisol reserve, including in pregnancy, and says there is no medical reason to avoid a single diagnostic dose in a pregnant woman. The Summary (p. 1) recommends the test when clinically feasible, alongside paired cortisol and ACTH measurements. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [41] 41. Suri D, Moran J, Hibbard JU, Kasza K, Weiss RE. Assessment of adrenal reserve in pregnancy: defining the normal response to the adrenocorticotropin stimulation test. J Clin Endocrinol Metab. 2006;91:3866 -3872. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Patients with diseases such as nephrotic syndrome (43) and liver disease (50) as well as those who are in the immediate postoperative period (51) or who require intensive care (52) may have lower CBG and albumin and hence, lower cortisol measurements.”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Not checked — no full text of the sourcecites [43] 43. Klose M, Lange M, Rasmussen AK, et al. Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents. J Clin Endocri- nol Metab. 2007;92:1326 -1333. source
- Not checked — no full text of the sourcecites [50] 50. Vincent RP, Etogo-Asse FE, Dew T, Bernal W, Alaghband-Zadeh J, le Roux CW. Serum total cortisol and free cortisol index give different information regarding the hypothalamus-pituitary-adre- nal axis reserve in patients with liver impairment. Ann Clin Biochem. 2009;46:505-507. source
- Supportedcites [51] 51. le Roux CW, Chapman GA, Kong WM, Dhillo WS, Jones J, Alagh- band-Zadeh J. Free cortisol index is better than serum total cortisol in determining hypothalamic-pituitary-adrenal status in patients undergoing surgery. J Clin Endocrinol Metab. 2003;88:2045- 2048. source
For the part attributed to this source—the immediate postoperative period—the Results report that albumin and CBG fell after surgery, and that seven patients had unexpectedly low postoperative total cortisol. The Discussion attributes those low cortisol values to the fall in CBG. The other conditions in the citing sentence have separate citations. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [52] 52. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med. 2004;350: 1629 -1638. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interpretation of the diagnostic results requires thorough consideration of pregnancy-associated physiological changes of adrenocortical function (42).”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Supportedcites [42] 42. Jung C, Ho JT, Torpy DJ, et al. A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum. J Clin Endocrinol Metab. 2011;96:1533-1540. source
The Discussion (page not specified in the supplied passage) says that physiological hypercortisolism can be difficult to distinguish from Cushing’s syndrome during pregnancy and emphasizes trimester-specific reference ranges. This supports considering pregnancy-related adrenocortical changes when interpreting diagnostic results. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“An elevated ACTH concentration in the presence of a cortisol in the normal range can be the first sign of early-stage PAI (68).”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Could not verifycites [68] 68. Baker PR, Baschal EE, Fain PR, et al. Haplotype analysis discrim- inates genetic risk for DR3-associated endocrine autoimmunity and helps define extreme risk for Addison's disease. J Clin Endo- crinol Metab. 2010;95:E263-E270. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that 21-hydroxylase autoantibodies usually precede overt Addison’s disease and proposes subsequent adrenal-function testing. Neither that passage nor the passages retrieved by searching for ACTH, cortisol, and early adrenal insufficiency addresses whether elevated ACTH with normal-range cortisol can be an early sign of PAI. (LLM, conf=0.73)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
118 more claims · 24 with their cited sources checked
Create a free account to see all 194 claims and every source verdict.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 58
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In children, glucocorticoid replacement therapy (GCCrt) should be started with hydrocortisone (HC) at a total daily dose of 10 mg/m2, with dose titration according to individual needs (35).”
From X-linked adrenoleukodystrophy and primary adrenal insufficiency (2023) · cites this paper as [35]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“no drug suitably mimics the diurnal pattern of cortisol”
From Modeling Congenital Adrenal Hyperplasia and Testing Interventions for Adrenal Insufficiency Using Donor-Specific Reprogrammed Cells (2018) · cites this paper as Bornstein et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In such cases, a GC dosage increase of 20% to 40% from the 24th week onward is often beneficial (215).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [215]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, no consensus exists regarding the optimal dose and hydrocortisone delivery mode during major stress, and current recommendations are empirical rather than evidence-based (7, 17).”
From Prevention of adrenal crisis: cortisol responses to major stress compared to stress dose hydrocortisone delivery (2020) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In primary and secondary adrenal insufficiency, peak cortisol levels < 500 nmol/L (< 18.1 μg/dL), depending on assay, are indicative of adrenal insufficiency (38, 39).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [38]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > 2.2
“We suggest the low-dose (1 g) corticotropin test for diagnosis of PAI only when the substance itself is in short supply.”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
“Thus, for practical reasons, the low-dose test may be applicable to situations when corticotropin is in short supply or for other structural or economic reasons.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in development of evidence-based guidelines (15).”
MethodSapolsky, R. M., Romero, L. M., & Munck, A. U. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.1.0389 · Cited by 7,541 · cited 1×
“Enhanced glucocorticoid secretion in critical illness is considered necessary to prevent defense mechanisms (eg, cytokine release) from overshooting with concomitant detrimental toxicity (142, 143).”
BackgroundSapolsky, R. M. (2000) · Endocrine Reviews · doi:10.1210/er.21.1.55 · Cited by 7,533
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458 · cited 1×
“In newborns and children, mineralocorticoid sensitivity is lower, thereby usually requiring higher fludrocortisone doses compared to adults (106).”
BackgroundSpeiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468 · cited 4×
“a 17-OHprogesterone 1000 ng/dL is diagnostic for 21-OH deficiency (14).”
BackgroundMethodInfluentialSelf-citationORENTREICH, N., BRIND, J. L., RIZER, R. L., & VOGELMAN, J. H. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-3-551 · Cited by 1,349 · cited 1×
“Serum DHEAS concentrations physiologically peak between ages 20 and 30 years, followed by a gradual decline that is independent of menopause (113).”
BackgroundSpeiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationCorticosteroid insufficiency in acutely ill patients
Cooper, M. S., & Stewart, P. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020529 · Cited by 1,033
Marik, P. E., Pastores, S. M., Annane, D., Meduri, G. U., Sprung, C. L., Arlt, W., Keh, D., Briegel, J., Beishuizen, A., Dimopoulou, I., et al. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31817603ba · Cited by 912 · cited 1×
“Although similar arguments for the utility of the low-dose test have been proposed for other special diagnostic challenges such as the detection of adrenal insufficiency in critically ill patients (critical illness-related corticosteroid insufficiency), more evidence is needed to support such a formal recommendation (…”
BackgroundSelf-citationPharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886 · cited 1×
“Because of the short plasma half-life of hydrocortisone (approximately 90 min) (90), multiple dosing is recommended to mimic physiological conditions.”
Background
Research works printed but not linked: 3
- [29]29. Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insuffi- ciency. Ann Intern Med. 2003;139:194 -204.
- [110]110. Keilholz U, Guthrie GP Jr. Adverse effect of phenytoin on miner- alocorticoid replacement with fludrocortisone in adrenal insuffi- ciency. Am J Med Sci. 1986;291:280 -283.
- [177]177. Gan EH, MacArthur K, Mitchell AL, et al. Residual adrenal func- tion in autoimmune Addison's disease: improvement after tetra- cosactide (ACTH1-24) treatment. J Clin Endocrinol Metab. 2014; 99:111-118.
Cited by
Items 301–400 of 1,752
Russian clinical practice guidelines «congenital adrenal hyperplasia»
Mokrysheva, N. G., Mel'nichenko, G. A., Adamyan, L. V., Troshina, E. A., Молашенко, Н. В., Игоревна, С. А., Uvarova, E. V., Esayan, E. R. M., Andreeva, E. N., Ужегова, Ж. А., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12787 · Cited by 30
Choi, W., Kang, H., Kim, J., Kim, H. K., Kang, H., Lee, J., Kim, S., Stewart, R. J., & Kim, J. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.10.054 · Cited by 23
Ceccato, F., Torchio, M., Tizianel, I., Falb, M. P., Barbot, M., Sabbadin, C., Betterle, C., & Scaroni, C. M. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01889-1 · Cited by 25
“Plasma renin activity in the upper normal range has been found to be a useful marker for identifying a correct MC dose [1].”
InfluentialAutoimmune primary adrenal insufficiency -current diagnostic approaches and future perspectives
Wolff, A. S. B., Kucuka, I., & Oftedal, B. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1285901 · Cited by 32
Chantzichristos, D., Persson, A., Eliasson, B., Miftaraj, M., Franzén, S., Svensson, A., & Johannsson, G. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0751 · Cited by 24
Vidmar, A. P., Weber, J., Monzavi, R., Koppin, C. M., & Kim, M. S. (2018) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2017-0435 · Cited by 21
Rushworth, R. L., Chrisp, G. L., & Torpy, D. J. (2018) · Endocrine Practice · doi:10.4158/ep-2017-0117 · Cited by 22
Self-citationOpioid induced adrenal insufficiency: what is new?
Donegan, D. M. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000474 · Cited by 24
Ebrahimi, F., Widmer, A., Wagner, U., Müeller, B., Schüetz, P., Christ‐Crain, M., & Kutz, A. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0469 · Cited by 21
The management of glucocorticoid deficiency: Current and future perspectives
Dineen, R., Martin‐Grace, J., Thompson, C. J., & Sherlock, M. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.006 · Cited by 21
Mineralocorticoid Dysfunction during Critical Illness: A Review of the Evidence
Nethathe, G. D., Cohen, J., Lipman, J., Anderson, R., & Feldman, C. H. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003365 · Cited by 22
“There are currently no internationally accepted standardized methodologies of assessment, and reference material and reporting units for both aldosterone and renin also differ.(66,139,140) The diagnosis of hypoaldosteronism based on renin and aldosterone measurements using reference ranges obtained from non–critically…”
BackgroundInfluentialEvolving pituitary hormone deficits in primarily isolated GHD: a review and experts’ consensus
Binder, G., Schnabel, D., Reinehr, T., Pfäffle, R. W., Dörr, H., Bettendorf, M., Hauffa, B. P., & Woelfle, J. (2020) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-020-00108-2 · Cited by 24
“Glucocorticoid replacement should be based on the general dose recommendations, wellbeing and physical vitality of the patient, physiological increase in body weight, normal fat distribution, normal height velocity, and normal blood pressure as suggested for patients with primary adrenal insufficiency [38].”
BackgroundMunro, V., Elnenaei, M., Doucette, S., Clarke, D. B., & Imran, S. A. (2018) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.02.010 · Cited by 20
Mak, I. Y. F., Au Yeung, B. Y. T., Ng, Y. W., Choi, C. H., Iu, H. Y. P., Shek, C. C., & Tiu, S. C. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2016-1056 · Cited by 20
The spectrum of pediatric adrenal insufficiency: insights from 34 years of experience
Ventura, M., Caetano, J. S., Cardoso, R., Dinis, I., Melo, M., Carrilho, F., & Mirante, A. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2019-0030 · Cited by 20
Hydrocortisone with fludrocortisone for septic shock: a systematic review and meta‐analysis
Yamamoto, R., Nahara, I., Toyosaki, M., Fukuda, T., Masuda, Y., & Fujishima, S. (2020) · Acute Medicine & Surgery · doi:10.1002/ams2.563 · Cited by 29
Gasco, V., Bima, C., Geranzani, A., Giannelli, J., Marinelli, L., Bona, C., Cambria, V., Berton, A. M., Prencipe, N., Ghigo, E., et al. (2021) · Neuroendocrinology · doi:10.1159/000514216 · Cited by 18
Management of Patients With Glucocorticoid-Related Diseases and COVID-19
Chifu, I. O., Detomas, M., Dischinger, U., Kimpel, O., Megerle, F., Hahner, S., Faßnacht, M., & Altieri, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.705214 · Cited by 23
“org 5 Ensuring that AI patients receive the necessary education regarding “sick day rules” and are equipped with an emergency pass, an emergency kit, and adequate supplies of immediaterelease glucocorticoids is mandatory for their optimal selfmanagement in the event of an imminent adrenal crisis (25, 39, 55).”
BackgroundInfluentialHamazaki, K., Nishigaki, T., Kuramoto, N., Oh, K., & Konishi, H. (2022) · Cureus · doi:10.7759/cureus.23021 · Cited by 21
“The GST stimulates both ACTH and GH secretion like the ITT and can be a good alternative to the ITT because of the dangers posed by the ITT, whereas it has yet to be considered the gold standard test [13].”
BackgroundAdrenal Gland Function and Dysfunction During COVID-19
Kanczkowski, W., Gaba, W. H., Krone, N. P., Varga, Z., Beuschlein, F., Hantel, C., Andoniadou, C. L., & Bornstein, S. R. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1873-2150 · Cited by 23
Self-citationMohammedi, K., Bertherat, J. Y., Raverot, G., Drui, D., Reznik, Y., Castinetti, F., Chanson, P., Manon, F., Brossaud, J., & Tabarin, A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad251 · Cited by 21
Nethathe, G. D., Lipman, J., Anderson, R., Fuller, P. J., & Feldman, C. H. (2023) · British Journal of Anaesthesia · doi:10.1016/j.bja.2023.10.034 · Cited by 27
Eriksson, D., Dalin, F., Eriksson, G. N., Landegren, N., Bianchi, M., Hallgren, Å., Dahlqvist, P. M., Wahlberg, J., Ekwall, O., Winqvist, O., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01957 · Cited by 20
Self-citationGroup 4: Replacement therapy for adrenal insufficiency
Castinetti, F., Guignat, L., Bouvattier, C. M., Samara‐Boustani, D., & Reznik, Y. (2017) · Annales d Endocrinologie · doi:10.1016/j.ando.2017.10.007 · Cited by 20
Applicability and added value of novel methods to improve drug development in rare diseases
Mitroiu, M., Rengerink, K. O., Pontes, C., et al. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0925-0 · Cited by 20
Current Knowledge and Practices of Heath Care Professionals on Opioid-Induced Adrenal Insufficiency
Saeed, Z. I., Bancos, I., & Donegan, D. (2019) · Endocrine Practice · doi:10.4158/ep-2019-0177 · Cited by 20
Yedinak, C. G., Cetas, I., Ozpinar, A., McCartney, S., Dog⫧an, A., & Fleseriu, M. (2016) · Endocrine · doi:10.1007/s12020-016-1042-2 · Cited by 20
Genetic aetiology of primary adrenal insufficiency in Chinese children
Chang, Z., Lu, W., Zhao, Z., Li, X., Li, X., Ye, R., Ni, J., Zhou, P., Zhang, M., Cheng, R., et al. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-01021-x · Cited by 21
A Contemporary Approach to the Diagnosis and Management of Adrenal Insufficiency
Charoensri, S., & Auchus, R. J. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1894 · Cited by 28
“Prescribed in doses ranging from 3 to 5 mg/day, prednisolone, however, is cost-effective and can be administered once daily, making it a potential alternative to hydrocortisone, particularly in patients with difficulty taking midday doses [4].”
BackgroundInfluentialIoakim, K. J., Sydney, G. I., & Paschou, S. Α. (2019) · HORMONES · doi:10.1007/s42000-019-00147-z · Cited by 20
Goyal, A., Kubihal, S., Gupta, Y., Jyotsna, V. P., & Khadgawat, R. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_553_19 · Cited by 21
Sævik, Å. B., Wolff, A. B., Björnsdottir, S., Simunkova, K., Hynne, M. S., Dolan, D. W. P., Bratland, E., Knappskog, P. M., Methlie, P., Carlsen, S., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa202 · Cited by 19
“In autoimmune Addison’s disease (AAD), patients suffer from deficiency of glucocorticoids (GCs) and mineralocorticoids due to autoimmune destruction of the adrenal cortex, a fatal condition if left untreated [1].”
BackgroundSelf-citationAdrenal crisis and mortality rate in adrenal insufficiency and congenital adrenal hyperplasia
Lousada, L. M., Mendonca, B. B., & Bachega, T. A. S. S. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000392 · Cited by 32
“Mineralocorticoid replacement is not required if the hydrocortisone dose exceeds 50 mg/24 h due to the mineralocorticoid effect of high hydrocortisone dosage (Table 2) (2,27,33,42).”
BackgroundInfluentialAdrenal insufficiency in HIV/AIDS: a review
Mifsud, S., Gauci, Z., Gruppetta, M., Mallia Azzopardi, C., & Fava, S. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1979393 · Cited by 19
Adrenal crises in adolescents and young adults
Rushworth, R. L., Chrisp, G. L., Bownes, S., Torpy, D. J., & Falhammar, H. (2022) · Endocrine · doi:10.1007/s12020-022-03070-3 · Cited by 19
Self-citationTransition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis
Brucato, A. L., Wheeler, A., Luis, S. A., Abbate, A., Cremer, P. C., Zou, L., Insalaco, A., LeWinter, M. M., Lewis, B. S., Lin, D., et al. (2022) · Heart · doi:10.1136/heartjnl-2022-321328 · Cited by 20
ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow
Birtolo, M. F., Antonini, S., Saladino, A., Zampetti, B., Lavezzi, E., Chiodini, I., Mazziotti, G., Lania, A. G. A., & Cozzi, R. (2023) · Biomedicines · doi:10.3390/biomedicines11030904 · Cited by 19
“The diagnosis of PAI is usually overt and is based on clinical signs and symptoms (often the ones of an adrenal crisis), possibly combined with skin hyperpigmentation, very low serum cortisol in the morning, and high ACTH [5] and since confirmatory stimulation tests are not always required, most centers do not routine…”
BackgroundMethodAhmet, A. H., Tobin, R., Dang, U. J., Rooman, R., Guglieri, M., Clemens, P. R., Hoffman, E. P., & Ward, L. M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae521 · Cited by 23
Rushworth, R. L., Chrisp, G. L., Dean, B., Falhammar, H., & Torpy, D. J. (2017) · Hormone Research in Paediatrics · doi:10.1159/000479370 · Cited by 17
Self-citationApproach to the Patient With New-Onset Secondary Amenorrhea: Is This Primary Ovarian Insufficiency?
Stuenkel, C. A., Gompel, A., Davis, S. R., Pinkerton, J. V., Lumsden, M. A., & Santen, R. J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab766 · Cited by 23
Herath, M., Langdahl, B. L., Ebeling, P. R., & Milat, F. (2021) · Clinical Endocrinology · doi:10.1111/cen.14637 · Cited by 21
Autoimmune Thyroid Disorders in Autoimmune Addison Disease
Stokland, A. M., Ueland, G. Å., Lima, K., Grønning, K., Finnes, T. E., Svendsen, M., Tomkowicz, A., Holte, S. E., Sollid, S. T., Dębowska, A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac089 · Cited by 22
Self-citationGupta, S., Ansari, M. A. M., Gupta, A. K., Chaudhary, P., & Bansal, L. K. (2022) · The Surgery Journal · doi:10.1055/s-0042-1743523 · Cited by 19
Diagnosis and Management of Adrenal Insufficiency and Adrenal Crisis in the Emergency Department
Lentz, S. A., Collier, K. C., Willis, G., & Long, B. (2022) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2022.06.005 · Cited by 23
Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review
Profili, N. I., Castelli, R., Gidaro, A., Merella, A., Manetti, R., Palmieri, G., Maioli, M., & Delitala, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155161 · Cited by 19
The risk for hypoglycemia during Ramadan fasting in patients with adrenal insufficiency
Chihaoui, M., Grira, W., Bettaieb, J., Yazidi, M., Chaker, F., Rejeb, O., Oueslati, I., Feki, M., Kaabachi, N., & Slimane, H. (2017) · Nutrition · doi:10.1016/j.nut.2017.07.014 · Cited by 19
Mehta, S., & Brar, P. C. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2019-0075 · Cited by 18
Yamagata, S., Kageyama, K., Takayasu, S., Asari, Y., Makita, K., Terui, K., & Daimon, M. (2019) · Internal Medicine · doi:10.2169/internalmedicine.3008-19 · Cited by 20
Serum Morning Cortisol as A Screening Test for Adrenal Insufficiency
Montes‐Villarreal, J., Pérez-Arredondo, L. A., Rodríguez‐Gutiérrez, R., González-Colmenero, A. D., Solís, R. C., González‐González, J. G., & Mancillas‐Adame, L. G. (2019) · Endocrine Practice · doi:10.4158/ep-2019-0327 · Cited by 19
Chihaoui, M., Mimita, W., Oueslati, I., Rejeb, O., Amor, Z. B., Grira, W., Yazidi, M., & Chaker, F. (2019) · Endocrine · doi:10.1007/s12020-019-02082-w · Cited by 18
Luigi, L. D., Pigozzi, F., Sgrò, P., Frati, L., Gianfrancesco, A. D., & Cappa, M. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01145-z · Cited by 22
Approach to the Patient with Subclinical Cushing’s Syndrome
Ivović, M., Marina, L., Šojat, A. S., Tančić‐Gajić, M., Arizanović, Z., Kendereški, A., & Vujović, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200813134328 · Cited by 20
Monti, S., Presciuttini, F., Deiana, M. G., Motta, C., Mori, F., Renzelli, V., Stigliano, A., Toscano, V., Pugliese, G., & Poggi, M. (2021) · Thyroid · doi:10.1089/thy.2021.0040 · Cited by 23
“5 mg/day, according to the weight and clinical conditions (5).”
BackgroundMethodResultInfluentialAdrenal cortex–medulla interactions in adaptation to stress and disease
Bornstein, S. R., Berger, I., Scriba, L. D., Santambrogio, A., & Steenblock, C. (2019) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2019.06.005 · Cited by 19
Self-citationPre-test cortisol levels in predicting short synacthen test outcome: a retrospective analysis
Ravindran, R., Carter, J. L., Kumar, A., Capatana, F., Khan, I. N., Adlan, M. A., & Premawardhana, L. D. (2022) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514221093316 · Cited by 17
“17 We acknowledge that this strategy may result in between 7% and12% false positive results (which normalise in the 60 minute post Synacthen sample in the 60 minute SST) but have done so in line with local practice and pragmatic reasons.”
Melin, J., Parra-Guillen, Z. P., Hartung, N., Huisinga, W., Ross, R. J., Whitaker, M. J., & Kloft, C. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0575-8 · Cited by 17
Fredrick, F. C., Meda, A. K. R., Singh, B. P., & Jain, R. (2024) · Acute and Critical Care · doi:10.4266/acc.2024.00647 · Cited by 22
Sobolewska, J., Działach, Ł., Kuca, P., & Witek, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1473151 · Cited by 23
Fertility and pregnancy in women with primary adrenal insufficiency
Bensing, S., Giordano, R., & Falorni, A. (2020) · Endocrine · doi:10.1007/s12020-020-02343-z · Cited by 20
Deligiorgi, M. V., & Trafalis, D. T. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107050 · Cited by 18
Endocrinopathies in Inborn Errors of Immunity
Takasawa, K., Kanegane, H., Kashimada, K., & Morio, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786241 · Cited by 19
ABCD1 Gene Mutations: Mechanisms and Management of Adrenomyeloneuropathy
Volmrich, A. M., Cuénant, L. M., Forghani, I., Hsieh, S. L., & Shapiro, L. T. (2022) · The Application of Clinical Genetics · doi:10.2147/tacg.s359479 · Cited by 21
“Patients with mineralocorticoid deficiency should be advised against restricting their salt consumption.(118) Intermittent fasting should generally be avoided, though it may be an important part of some religious observances.”
BackgroundLeucht, K., Ali, N., Foller, S., & Grimm, M. (2022) · Cancers · doi:10.3390/cancers14184369 · Cited by 25
“Adrenal insufficiency may manifest with various nonspecific symptoms (signs of dehydration, hyperkalemia, hyponatremia, hypotension, dizziness, possibly shock); occasionally, acute adrenal insufficiency may occur [32].”
BackgroundThe Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events
Mytareli, C., Ziogas, D. C., Karampela, A., Papalexis, P., Siampanopoulou, V., Lafioniatis, A., Benopoulou, Ο., Gogas, H. J., & Angelousi, A. G. (2023) · Cancers · doi:10.3390/cancers15072016 · Cited by 20
“Based on the ESE guidelines [45], patients with suspected adrenal crisis should be treated with an immediate parenteral injection of 100 mg (50 mg/m2 for children) hydrocortisone, followed by appropriate fluid resuscitation and 200 mg (50–100 mg/m2 for children) of hydrocortisone/24 h (via continuous IV therapy or 6 h…”
InfluentialAdrenal Failure: An Evidence-Based Diagnostic Approach
Shaikh, S., Nagendra, L., Shaikh, S. S., & Pappachan, J. M. (2023) · Diagnostics · doi:10.3390/diagnostics13101812 · Cited by 23
“A stimulated peek cortisol level of ≥500 nmol/L (18 μg/dL) excludes adrenal insufficiency as per the current international guidelines [23].”
BackgroundChacón, A. G. M., Wang, C., Waqar, D., Syeda, S. A., Kumar, R., & Meghana, D. R. (2023) · Cureus · doi:10.7759/cureus.38948 · Cited by 29
“Although guidelines for diagnosing and managing primary or secondary adrenal insufficiency and adrenal crisis have been proposed, there are also guidelines specifically for glucocorticoid-induced adrenal insufficiency [45, 92-95].”
BackgroundEndocrinopathies Associated With Immune Checkpoint Inhibitor Use
Kotwal, A., Kennedy, R., Kikani, N. J., Thosani, S., Goldner, W. S., & Shariff, A. I. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.03.023 · Cited by 22
Hong, A. R., Ryu, O., Kim, S. Y., Kim, S. W., The Korean Adrenal Gland and Endocrine Hypertension Study Group, & Korean Endocrine Society (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.4.466 · Cited by 20
An overview of inborn errors of metabolism manifesting with primary adrenal insufficiency
Hannah‐Shmouni, F., & Stratakis, C. A. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9447-2 · Cited by 18
Self-citationFinancial Conflicts of Interest Among Authors of Endocrine Society Clinical Practice Guidelines*
Irwig, M. S., Kyinn, M., & Shefa, M. C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00526 · Cited by 20
Goubar, T., Torpy, D. J., McGrath, S., & Rushworth, R. L. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00263 · Cited by 17
Self-citationHussain, S., Hussain, S., Mohammed, R., Meeran, K. M., & Ghouri, N. (2020) · Clinical Endocrinology · doi:10.1111/cen.14250 · Cited by 24
Laakso, S. M., Holopainen, E., Betterle, C., Saari, V., Vogt, E., Schmitt, M. M., Winer, K. K., Kareva, M., Sabbadin, C., Husebye, E. S., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab705 · Cited by 17
Self-citationTurla, A., Laganà, M., Grisanti, S., Abate, A., Ferrari, V. D., Cremaschi, V., Sigala, S., Consoli, F., Cosentini, D., & Berruti, A. (2022) · Endocrine · doi:10.1007/s12020-022-03075-y · Cited by 19
Chye, A., Allen, I., Barnet, M. B., & Burnett, D. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894015 · Cited by 17
The side effects of immune checkpoint inhibitor therapy on the endocrine system
Goyal, I., Pandey, M. R., Sharma, R. K., Chaudhuri, A., & Dandona, P. (2021) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_313_19 · Cited by 18
Suspected ontogeny of a recently described hypo-androgenic PCOS-like phenotype with advancing age
Gleicher, N., Kushnir, V. A., Darmon, S. K., Wang, Q., Zhang, L., Albertini, D. F., & Barad, D. H. (2018) · Endocrine · doi:10.1007/s12020-017-1498-8 · Cited by 18
Presence, patterns & predictors of hypocortisolism in patients with HIV infection in India
Sharma, N., Sharma, L. K., Anand, A., Gadpayle, A. K., Gaurav, K., Mukherjee, S., Kulshreshtha, B., & Dutta, D. (2018) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_43_16 · Cited by 17
An update on the diagnosis and treatment of adrenoleukodystrophy
Gujral, J., & Sethuram, S. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000782 · Cited by 21
“Hydrocortisone is the preferred glucocorticoid in the pediatric age group given the least growth suppressive effects and can be administered between the dose range of 8–12mg/m(2)/day [50].”
BackgroundOno, Y., Ono, S., Yasunaga, H., Matsui, H., Fushimi, K., & Tanaka, Y. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0803 · Cited by 17
Treatment of Addison’s disease during pregnancy
Oliveira, D., Lages, A. D. S., Paiva, S., & Carrilho, F. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-17-0179 · Cited by 16
Ortiz-Flores, A. E., Santacruz, E., Mendiguchía, L. J., Cano, A. M. G., Nattero‐Chávez, L., Escobar-Morreale, H. F., & Luque‐Ramírez, M. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019273 · Cited by 17
Daily adjustment of glucocorticoids by patients with adrenal insufficiency
Schöfl, C., Mayr, B. M., Maison, N., Beuschlein, F., Meyer, G., Badenhoop, K. W. J., Kienitz, T., & Quinkler, M. O. (2019) · Clinical Endocrinology · doi:10.1111/cen.14004 · Cited by 19
Adrenal disorders in pregnancy, labour and postpartum – an overview
Manoharan, M., Sinha, P., & Sibtain, S. (2019) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2019.1648395 · Cited by 18
“…of AD is with replacement doses of steroids (hydrocortisone 15–25mg in 2–3 divided doses) and fludrocortisone (50–100mcg), hydrocortisone is the preferred steroid in pregnancy as it does not cross the placenta and is more physiological than other available glucocorticoids (Bornstein et al. 2016).”
BackgroundInfluentialCongenital hypothyroidism, cardiac defects, and pancreatic agenesis in an infant with GATA6 mutation
Raghuram, N., Marwaha, A., Greer, M. C., et al. (2020) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.61569 · Cited by 16
“…following an inadequate response to administration of 30 μcg/kg/dose (47.5 μcg) of cosyntropin (baseline cortisol = 86 nmol/L, 1 hr post cosyntropin cortisol = 338 nmol/L; which failed to raise above the threshold of 500 nmol/L required for an adequate adrenal response [Bornstein et al., 2016]).”
BackgroundInfluentialMilluzzo, A., Falorni, A., Brozzetti, A., Pezzino, G., Tomaselli, L. G., Tumminia, A., Frittitta, L., Vigneri, R., & Sciacca, L. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.09.012 · Cited by 18
Druce, I., Tawagi, K., Shaw, J. L. V., Ibrahim, A. M., Lochnan, H. A., & Ong, M. (2022) · Current Oncology · doi:10.3390/curroncol29070370 · Cited by 17
“Morning serum cortisol values below 80–140 nmol/L (3–5 mcg/dL) indicate insufficiency and do not require additional testing [14], while it is generally accepted that levels of greater than 275 nmol/L (10 mcg/dL) rule insufficiency out reliably [15], although some sources are more stringent and would suggest that only…”
BackgroundMethodInfluentialObrynba, K. S., Hoffman, R. P., Repaske, D. R., Anglin, K., & Kamboj, M. K. (2018) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2017-0487 · Cited by 18
De Novo Design of High-Performance Cortisol Luminescent Biosensors
Chen, J. Y.-H., Peng, X., Xi, C., Lee, G. R., Baker, D. A., & Yeh, A. H.-W. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c05004 · Cited by 18
Chesover, A., Millar, H., Sepiashvili, L., Adeli, K., Palmert, M. R., & Hamilton, J. K. (2019) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz030 · Cited by 15
“Glucocorticoid insufficiency is traditionally defined by a peak cortisol less than 500 nmol/L on a 250 mcg ACTH stimulation test [10].”
Casale, M., Baldini, M., Monte, P. D., Gigante, A., Grandone, A., Origa, R., Poggi, M., Gadda, F., Lai, R., Marchetti, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071826 · Cited by 21
Tomkins, M., Martin‐Grace, J., Kennedy, C., McEnroe, O., Heverin, K., Srinivasan, S., Little, D. M., Conlon, P. J., de Freitas, D. G., Denton, M., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac044 · Cited by 17
“The gold standard for diagnosis of AI is dynamic stimulatory testing [17], which has resource implications when considering screening a large patient population.”
BackgroundInfluentialWhitaker, M. J., Huatan, H., & Ross, R. J. M. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01183-w · Cited by 20
“Since the 1960s, patients with adrenal insufficiency have been replaced with hydrocortisone (the synthetic form of the endogenous hormone, cortisol); however, despite replacement, patients still have an increased mortality, up to 5 times that of the healthy population, patients feel tired, and those with CAH have poor…”
BackgroundClaude, F., Ubertini, G., & Szinnai, G. (2022) · Children · doi:10.3390/children9111617 · Cited by 23
“According to the current literature, 8–10 mg/m2/day in three divided doses is suggested for adrenal insufficiency [46,47].”
BackgroundApproach to the Patient: Preventing Adrenal Crisis Through Patient and Clinician Education
Ahmet, A. H., Gupta, A., Malcolm, J., & Constantacos, C. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad003 · Cited by 20
Tuberculosis of Adrenal Glands—A Population-based Case-control Study
Lindh, J. D., Patrova, J., Rushworth, R. L., Mannheimer, B., & Falhammar, H. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad047 · Cited by 22
“Thus, it is important to evaluate the cortisol function, and if it is low, also the aldosterone function in patients with tuberculosis, especially in those with adrenal lesions and those presenting with nonspecific symptoms such as fatigue, malaise, postural dizziness, musculoskeletal and abdominal pain, depression, a…”
BackgroundSerum cortisol assay performance following the 1 mg overnight dexamethasone suppression test
Atkins, J. S., Hawley, J. M., Owen, L. J., Clayton, J. C., Scargill, J., & Keevil, B. G. (2023) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632231179560 · Cited by 16
Real world evidence supports waking salivary cortisone as a screening test for adrenal insufficiency
Debono, M., Caunt, S., Elder, C. J., Fearnside, J., Lewis, J., Keevil, B. G., Dixon, S., & Ross, R. J. M. (2023) · Clinical Endocrinology · doi:10.1111/cen.14975 · Cited by 21
“5,6 It is estimated that 90,000 ASTs are performed a year in the United Kingdom.”
BackgroundAddison’s disease in antiphospholipid syndrome: a rare complication
Oliveira, D., Ventura, M., Melo, M., Paiva, S., & Carrilho, F. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-18-0118 · Cited by 15
Broersen, L. H. A., van Haalen, F. M., Kienitz, T., Dekkers, O. M., Strasburger, C. J., Pereira, A. M., & Biermasz, N. R. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0202 · Cited by 19
Metadata
- Authors
- Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., & Torpy, D. J.
- Affiliations
- King's College London (GB)
- Mayo Clinic (US)
- National Institutes of Health (US)
- Royal Adelaide Hospital (AU)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-02
- Volume
- 101
- Issue
- 2
- Pages
- 364-389
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC4880116
- OpenAlex
- W2234917292
- Cited by
- 1,769
- References
- 222
- Citations by year
- 2026: 187 · 2025: 198 · 2024: 180 · 2023: 191 · 2022: 180 · 2021: 206 · 2020: 165 · 2019: 149 · 2018: 148 · 2017: 102 · 2016: 54
- FWCI
- 151.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, cc-by-nc-nd)
- Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by-nc-nd)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- European Society of Endocrinology
- Novo Nordisk Fonden (NNF14OC0011005)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK062027)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- Addison's disease, diagnosis, hydrocortisone replacement, fludrocortisone, corticosteroid dose, stress dosing, 21-hydroxylase autoantibodies, autoimmune thyroid disease, pregnancy, glucocorticoid therapy, autoimmune adrenal insufficiency
- MeSH terms
- Adrenal Insufficiency, Female, Humans, Pregnancy, Societies, Medical, Evidence-Based Medicine, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.